Roche and Zealand Pharma reported mid‑stage data for petrelintide showing about 10.7% mean placebo‑controlled weight loss at 42 weeks, short of investor expectations and materially below competing mid‑stage readouts. Zealand’s shares plunged more than 30% on the results, and analysts flagged concerns about the drug’s ability to compete in a crowded GLP‑1 and amylin analogue market. Company communications emphasized the agent’s tolerability but acknowledged that efficacy may not meet the high bar set by recent competitors. The outcome raises questions about dose ceiling effects and whether higher dosing can materially increase weight loss without compromising safety. The trial result illustrates the escalating efficacy benchmark in obesity therapeutics and may reshape go‑forward positioning and phase III planning for amylin‑based candidates.